GlassScriptPhysician profile
Parastou Abedi
NPI 1720067333
$5,884.47
in general payments reported to CMS, 2019-2025
20 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.20 · 2020: $1,183 · 2021: $99.80 · 2022: $590 · 2023: $1,101 · 2024: $1,697 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,730.52 | 2020-2025 | Argos, Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $1,713.40 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $490.44 | 2020-2025 | Cequa |
| Abbvie INC. | $305.02 | 2022-2025 | Durysta |
| Oyster Point Pharma, INC. | $281.88 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $215.46 | 2025 | Xdemvy |
| Allergan, INC. | $185.23 | 2020-2022 | |
| Sight Sciences, INC. | $160.02 | 2022 | |
| Harrow Eye, LLC | $125.00 | 2024 | Vevye |
| Dompe US, INC. | $124.25 | 2023 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $98.25 | 2022-2024 | Tecnis Simplicity |
| Silk Road Medical, INC. | $93.00 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Horizon Therapeutics Plc | $78.72 | 2021-2023 | Tepezza |
| Thea Pharma INC. | $60.64 | 2022-2025 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $47.73 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.08 | 2024 | Tepezza |
| Glaukos Corporation | $42.79 | 2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $38.47 | 2020 | |
| Ocular Therapeutix, INC. | $29.37 | 2021 | |
| Shire North American Group INC | $20.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parastou Abedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.